ResearchPod Summary
Following traumatic brain injury (TBI), biochemical processes often initiate secondary neurodegeneration that persists for months or years, driven largely by chronic microglial activation. This study investigates whether delayed pharmacological activation of the metabotropic glutamate receptor 5 (mGluR5) can modulate this chronic inflammatory response and promote better long-term recovery in a mouse model.
Researchers used a controlled cortical impact (CCI) device to induce TBI in mice. One month after the injury—a time point reflecting chronic, established pathology—they administered a single dose of the mGluR5 agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG). Some mice were also treated with a selective mGluR5 antagonist, MTEP, to verify the receptor specificity of the treatment. The researchers assessed the impact of this intervention using T2-weighted MRI to measure lesion volume, diffusion tensor imaging (DTI) to examine white matter integrity, and behavioral tests (the beam walk and the Morris water maze) to evaluate motor and cognitive function. Histological analysis was conducted at four months post-injury to examine microglial phenotype and neuronal survival.
The study found that TBI triggers persistent mGluR5 expression in reactive microglia in the cortex and hippocampus, which are also characterized by the expression of the inflammatory enzyme NADPH oxidase. Delayed administration of CHPG significantly arrested lesion progression and preserved white matter tract integrity. Behavioral testing demonstrated that treated mice exhibited superior motor coordination and spatial memory compared to vehicle-treated controls. Histological examinations revealed that CHPG reduced the density of highly reactive (bushy or hypertrophic) microglia and increased the number of surviving hippocampal neurons. These beneficial effects were abolished by the co-administration of the mGluR5 antagonist, confirming that the neuroprotective results were mediated through mGluR5 activation.
These findings challenge the traditional view that the therapeutic window for neuroprotection in TBI is confined to the immediate post-injury period. By demonstrating that a single dose can modulate long-term, chronic neuroinflammation and preserve neurological function long after the initial trauma, this work provides a new potential therapeutic target and suggests that the period for meaningful intervention in TBI is much wider than previously assumed.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.